Pioneering rational design of drugs made of defined bacteria consortia that are essential dwellers of the gut ecosystem. The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer ! EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in …

123 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Speeding up the research revolution with you. DNAsimple, now part of Joined Bio, continues its mission to make participant engagement simple, secure, and rewarding. Through Joined Bio, we enable researchers to access qualified participants, biospecimens, and real-world data quickly and ethically, accelerating discovery and improving lives, all from the comfort of home. Together, we are building a more connected and transparent research ecosystem that bridges people and science. Request a quote today: https://joined.bio/quote-request/ genetics, genomics, biobanking, genetic research, saliva , DNA, DNA sample, microbiome, donor compensation, DNAsimple, healthcare research, and personalized medicine

96 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Our breakthroughs in immunology make Life Without Disease ® possible. La Jolla Institute for Immunology (LJI) Our breakthroughs in immunology make life without disease possible. We are a non-profit medical research institute dedicated to increasing knowledge and improving human health through studies of the immune system. We solely focus on the immune system because it holds the power to prevent, treat, and ultimately eliminate disease, extending healthy human life. At LJI, we accelerate lifesaving discoveries by combining a uniquely agile research environment with cutting-edge technology—empowering our world-class scientists to aim higher and move faster. What is immunology? Immunology is a …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unibiome develops fermentative microbes that have been engineered to produce vitamins and other healthy compounds and designed to be used with any fermentation-based food to increase its nutritional value. We believe that re-purposing the food microbiome is a game-changing approach to feeding 9 billion people by 2050. Biotechnology, Synthetic Biology, Design, Microbiology, and Food Fortification

106 similar entities Type: Startup Activities: biotech foodtech Technologies: Synthetic Biology

The next-gen software for biologics discovery We’re building the operating system for biology. Founded by scientists, our mission is to transform how R&D teams turn raw NGS data into therapeutic assets. By bridging the gap between biology and bioinformatics, we empower scientists to drive innovation without technical barriers. Our software, Platforma, combines an intuitive, no-code interface with white-box solutions tailored for in vivo and in vitro antibody discovery, translational research, and multi-omics. Built on the proven foundation of MiXCR, the world's leading immune profiling tool, we provide your R&D team with the unified intelligence to accelerate discovery and bring therapeutics …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: SaaS Data Analytics

Clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome field. Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.​ Committed to innovation, Da Volterra develops products intended to protect the intestinal …

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science of certainty Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile …

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing cancer care through microbiome profiling 🦠 Discover your microbiome: www.mybioma.com Biome Diagnostics GmbH (BiomeDx®) is an Austria-based MedTech company driving precision medicine through pioneering microbiome-based technologies that transform cancer care. At the intersection of state-of-the-art DNA sequencing and advanced machine learning, BiomeDx® develops first-in-class solutions for routine clinical practice. In addition to the lifestyle product myBioma (www.mybioma.com) for end-customers, the company focuses on medically certified products in the fields of gut microbiome and cancer. With ISO 9001 and ISO 13485 certifications, BiomeDx® is the first microbiome company worldwide with dual ISO certification — reflecting our commitment to safety and …

79 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Microbiology assays at previously impossible speeds and strain banks with amazing diversity ! Microbiology is what we do. Our unrelenting focus has enabled us to develop unique capabilities in ultra-high-throughput single-cell culture of microorganisms. Businesses in areas as diverse as pharma, agriculture, food, human health and environmental protection have partnered with us to gain powerful competitive advantages from our technology.So could yours. Our proprietary microfluidic platform is capable of : - identifying microbes of interest based on their functional characteristics among millions of candidates - perform a wide range of assays at previously impossible speeds - generate strain banks with …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A Microbiota biotherapeutics and Vaccines company. Conditioning the gut ecosystem for disease prevention and therapy. Spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, aimed at shaping the intestinal microbiota for the cure and prevention of diseases such as bowel diseases and cancer. The gut ecosystem conditions the function of all our organs and plays a fundamental role in our wellbeing. The mucosal immune system has co-evolved with the intestinal microbiota to adapt its function to a number of environmental and possibly pathogenic factors. MV Bio leverages a microbiota-mediated mechanism regulating the physiological response of the intestinal …

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Peptide Intelligence for Smarter Formulations Nature’s Most Powerful Peptides, Discovered by AI We use artificial intelligence to unlock cell-signaling peptide ingredients for your product formulations. Discovered by AI, validated by human clinical studies, ready for your innovations. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat, to what we apply to our skin. By translating nature’s wisdom into innovation, together, we can change the life of billions. Pure peptides, Peptide mixtures, Hydrolysates, Multi targeted peptides, Bioinformatics, Artificial intelligence for drug discovery, Peptide drugs, and …

141 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Part of Cmbio Eagle Genomics applies network science to biology. We are revealing the impact of the microbiome on humans, animals and the environment to secure a sustainable future for our food, water, soil and the health of our planet. Our mission is to deliver insight from the microbiome to profoundly change our understanding of wellness and even our fundamental assumptions about life on earth. Our platform transforms scientists’ journey to insights, unifying constellations of complex, multi-dimensional data (the data fabric) to explore and extract signals and networks of relationship, otherwise not detectable by humans alone. This is the frontier …

90 similar entities Type: Startup Activities: deeptech biotech it services Technologies: Data Analytics

Redefining microbiome-based therapeutics MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition …

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments. Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused …

278 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

298 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI-Native Phage Therapy We are facing a global crisis where bacterial infections are becoming increasingly deadly due to antibiotic resistance. The health and economic consequences are staggering, with bacterial disease predicted to be the #1 cause of death by 2050. Alternatives are urgently needed, but nature already has its solution: phages, the natural predators of bacteria. At Phagos, we are bringing back phage technology by combining advances in microbiology with cutting-edge artificial intelligence. Our patented technology makes large-scale, customized phage-based veterinary medicines possible for the first time. And soon we'll universalize the technology for human health too. Our mission is …

65 similar entities Type: Startup Activities: biotech healthtech Technologies: Decarbonization

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering the Health Microbiome Movement The gut microbiome (i.e: the microorganisms present in our intestine) plays a major role in maintaining our health. In case of dysfunction, the microbiome is linked to a large number of inflammatory, metabolic, and neurological diseases. The study of the microbiome opens many perspectives for tomorrow’s medicine. Pelican Health offers a solution enabling multiple sampling of the microbiome in-situ with a single oral administration, in a reliable, precise, simple to administer and non-invasive manner.

47 similar entities Type: Startup Activities: deeptech

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precise Insights for Better Health Delivering on our promise to identify any microbe, from any sample, anywhere in the world will take a team of dedicated, passionate, and experienced individuals. The members of our team at IDbyDNA have a strong track record of building successful organizations and bring a breadth of multi-disciplinary experience including; microbial genomics, bioinformatics, software engineering, laboratory medicine, and commercialization. In concert with the global community of researchers, clinicians, industry partners and policy makers, we will revolutionize microbial detection and bring new solutions to solve problems that are not currently addressable with today’s technologies.

135 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: SaaS

Microbial solutions and microbiome skincare with live bacteria In Lactobio we focus on the creation of new microbiome and microbial solutions to target and fight the problem of increasing infections caused by microorganisms being resistant to antibiotics. We work with the skin, vaginal, and gut microbiota to treat a variety of diseases – with projects spanning various pathogens. Lactobio has obtained very promising clinical results, with isolated lactic acid bacteria having a significant antibacterial activity against Staphylococcus aureus, Methicillin Resistant Staphylococcus aureus (MRSA) and other pathogens.

55 similar entities Type: Startup Activities: deeptech biotech

Stellate Therapeutics develops innovative microbiome-derived small molecules to treat neurodegenerative diseases. Stellate Therapeutics is a pre-clinical stage start-up company developing innovative microbiome-derived small molecules to treat neurodegenerative diseases. We utilize the microbiome for our drug portfolio and our research focuses on the gut-brain axis. Due to millions of years of co-evolution, complex metabolic interactions exist between humans and their gut bacteria and Stellate has uncovered a unique set of metabolites that are produced by the microbiome and are involved in the maintenance of health. Our first drug will be a treatment for Parkinson’s disease.

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Trilliome, we're dedicated to enhancing healthspan and quality of life through groundbreaking, microbiome-targeting precision nutraceuticals. Our innovative, plant-derived supplements are scientifically formulated to optimize gut and brain health by promoting beneficial bacteria while suppressing harmful ones. With a robust foundation in research and an unwavering commitment to sustainability, our solutions address the global health crisis resulting from poor lifestyle choices. Led by seasoned industry professionals with PhDs and MBAs and with extensive experience in life sciences and microbiome research, Trilliome aims to transform the gut health market and empower individuals worldwide to achieve optimal longevity. Join us on this …

72 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Our rational design approach in therapeutics offers a paradigm shift in disease, making the untreatable, treatable. We're pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements. Our approach centers around biomimicy selectively targeting central cascades that drive disease. Our lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.

168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Probiotic Agriculture: improving agricultural productivity through plant health BioIntrant integrates more than thirty years of research at the interface of agronomy, pedology, microbial ecology and bioinformatics, in order to develop biostimulants for modern and responsible agriculture. To do this, BioIntrant integrates the plant into its environment (plant triptych, soil structure, microorganisms) to promote its intrinsic capacity to defend itself. It is today possible, thanks to the most advanced technologies and knowledge of the microbial ecology of plants, to restore this natural balance. Biotechnology, Agriculture, Agronomy, Microbiology, Biostimulant, Bioinformatics, and Genomics

88 similar entities Type: Startup Activities: agritech biotech deeptech Technologies: Synthetic Biology

We create all-in-one instruments that make high-throughput single-cell workflows easy thanks to droplet microfluidics At LiveDrop, we develop, build, and sell cutting-edge instruments and methods for high-throughput screening of biological cells and organisms—down to the single-cell level—using microfluidic droplets. Our solutions enable faster, more precise screenings through highly efficient, fully integrated bioassays. LiveDrop’s flagship platform, ModaFlow 4L5C, revolutionises cell screening, drug discovery, and secretome analysis with unparalleled speed and precision. It supports a wide range of applications, including monoclonal antibody discovery, single-cell secretome-based bioassays, high-throughput spheroid manufacturing for drug testing, directed evolution of microbes, and enzyme discovery. We value collaboration …

343 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology Cancer continues to be a leading cause of disability and early mortality worldwide. Immune checkpoint blockade with PD/L-1 therapies such as Keytruda and Opdivo can induce complete and durable clinical responses in multiple tumors, a breakthrough in cancer treatment over the last decade. However, only around 20% of patients respond and many trials have failed Many R&D programs in multiple companies are attempting to improve the clinical efficacy of PD/L-1 therapies, but no solution is yet approved. Most of these approaches target T-cells or the tumour microenvironment. Patients with …

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

270 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

From Probiotics to PreciBiomics TargEDys is a French commercial-stage biotech company specialized in the development of precision probiotics, or PreciBiomic solutions. Our mission is to detect, transpose and make available microbiome-based innovations to answer global public health challenges. How? By translating microbiome fundamental research from prestigious French institutes such as the Inserm and IGFL to applied research in probiotics, understanding the molecular mechanism of action of our strains, and developing industrial processes and IP to propose turnkey science-backed probiotics. Our vision is to bring the microbiome to the heart of healthcare and harvest its immense potential to improve the quality …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable …

330 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Customer precision probiotics at scale. The human microbiome is one of the most important frontiers in modern health science. Changes in the gut microbiome—known as dysbiosis—are increasingly linked to conditions such as IBS, IBD, Crohn’s disease, metabolic disorders, autoimmune disease, and more. Yet despite the growing science, most solutions still rely on generic probiotics that ignore a fundamental reality: every person’s microbiome is unique. Flore is changing that. By combining and advanced informatics and 9+ years of aggregated data, Flore helps individuals understand their unique microbiome signature and delivers precision probiotics tailored to their biology. Our mission is to empower …

63 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Data Analytics

We're changing the trajectory of human health, one baby at a time. Intent on a world without debilitating disease. Infinant Health, Inc is a privately held company committed to changing the trajectory of human health, one baby at a time, through our deep understanding of infant nutrition and the gut microbiome. Years of proprietary research into the role of breast milk and its impact on human development led to our groundbreaking discovery of B. infantis EVC001, a natural bacterial strain foundational to infant immune health. Unfortunately, B. infantis had been almost completely eradicated from infants in developed countries due to …

49 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning

rethinking microbiome Mikrobiomik is a biopharmaceutical company created for the research and development of therapies based on the human microbiome. Our Mission At Mikrobiomik we develop innovative therapies based on intestinal microbiota to offer new therapeutic options in serious diseases with unmet medical needs. Through our FSPIM® technology, we work to restore the balance of the microbiome and provide healthcare professionals and patients with safe, standardized and accessible therapeutic solutions in clinical practice. Fecal microbiota transplant (FMT)

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Casting light on the microbiome We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life. microbiome, precision medicine, biotechnology, diagnostics, immuno-oncology, and companion diagnostics

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming Labs with AI and Automation Reshape Biotech is building the next generation of lab automation robots. Our customers are biotech companies tackling the world’s biggest problems - be it alternative protein development or sustainable agriculture. Reshape Biotech is the scaling factor for these companies, as we let researchers collaborate globally on experiments and increase their throughput >500x. The team is highly multi-disciplinary, employing everything from PhD’s in biology to hardware and software engineers. We work closely together, and you will be exposed to a truly vertical team. We’re a fast growing startup with an incredibly ambitious team, dead-set on …

135 similar entities Type: Startup Activities: deeptech biotech Technologies: Robotics

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

589 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the development of microbiome-based therapies using proprietary tools for their design and production. PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class solutions for unmet health and personal care needs Results through innovation. We are an innovative biotechnology group with two divisions. Our consumer health arm has commercial products for the personal care market addressing nail, skin, scalp and hair issues. NovaBiotics pharma division has advanced clinical-stage product candidates for medically unmet, life-limiting inflammatory, infectious and respiratory disease. Our highly disruptive solutions to personal care and health needs address significant global markets. biotechnology, biologics, infectious disease, and drug discovery & development

225 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Fueled by Connections to Transform Rare DiseasesTM Agios is a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with rare disease communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. Rooted in hematology, we combine deep biological expertise with real-world insights to advance a growing pipeline of medicines that reflect patients’ priorities. Our inclusive, collaborative culture sparks bold thinking and strengthens our connections – with each other and with the people we serve. Review our social media guidelines: https://www.agios.com/community-guidelines/ Biopharmaceuticals, Cellular Metabolism, and Rare …

312 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Unlocking the full potential of genetic medicines. At Nvelop, we are working to address the complex challenge of effectively delivering genetic medicines to target cells within the body (in vivo) in order to help treat patients with previously undruggable diseases. Our team is advancing two next-generation delivery platforms, started in the labs of our scientific co-founders Dr. David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung formerly of Mass General Hospital. We will use these platforms to build a pipeline of therapeutics internally and to enable strategic partners. We are building a culture and organization …

126 similar entities Type: Incubators & VCs Startup Activities: biotech deeptech Technologies: Synthetic Biology

The world's first and only at-home RNA test for precision nutrition | A Viome Life Sciences, Inc. Company Viome | A Viome Life Sciences, Inc. Company. We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck. Scientists have …

166 similar entities Type: Startup Activities: healthtech biotech deeptech it services Technologies: A.I. A.I. - Machine Learning Data Analytics

Provention Bio is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. At Provention Bio, we approach autoimmune disease differently than traditional pharma, with a clear focus on early interception. Before symptoms present, before irreversible damage is done to the bodies, minds, and lives of patients and families, and before it’s too late —this is where we operate. Our lead investigational product candidate is currently under review by the U.S. Food and Drug Administration (FDA) for the delay or prevention of clinical type 1 diabetes in at-risk individuals. …

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A Sundew company We are creating a potentially revolutionary algal platform technology. Thanks to major advances in algal genomics and molecular biology, microalgae can be engineered to express inexpensive therapeutic proteins and vaccines of economic value. The cost of the synthetic biology tools has dropped. We are building our technology based on solid, peer-reviewed science[1][2][3][4]. By using microalgae as an oral delivery vehicle, we can substantially cut the labor and post-processing production costs, allowing us to produce effective vaccines that are much more affordable and user-friendly. Our technology can reduce or eliminate the use of antibiotics, reduce fish mortality rates …

89 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating innate immunity to improve cancer therapy outcomes. . Akthelia Pharma is a late preclinical-stage immunotherapy company, with its HQ in Iceland, targeting a huge unmet opportunity to improve cancer and cell/organ transplant outcomes through reducing the risk of neutropenic sepsis. This potentially fatal complication of systemic anticancer treatment, where a combination of reduced neutrophil count and loss of GI integrity results in bacteremia from the patient's own microbiome, is the leading cause of death associated with chemotherapy (up to 20% mortality) -- other than disease progression. Our breakthrough patented strategy, which is supported by world-leading KOLs, is to specifically …

84 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Formulating the Future of BiologicsTM Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are …

276 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

BaseClear offers genomics expertise and consultancy to accelerate the understanding and use of microorganisms. Microbes have a huge potential to contribute to the solution of a large number of issues facing the modern world, ranging from antibiotic resistance and personal disease to poor crop yields and problems caused by global warming. For years, relatively little was known about the often-invisible world of microbes. However, the latest DNA technologies have provided tools to really see what is happening inside microbes and within microbial communities. This allow us to unravel the interactions between microbes and their hosts and environment. BaseClear, founded in …

73 similar entities Type: SMB Activities: biotech deeptech